Abstract
Purpose
The feasibility of intracellular mdr1 mRNA expression detection with radiolabeled antisense oligonucleotide (ODN) was investigated in the murine leukemia cell line, P388/S, and its subclonal, adriamycin-resistant cell line, P388/R.
Methods
The expression level of mdr1 mRNA was analyzed by reverse transcription-polymerase chain reaction (RT-PCR). Existence of the multidrug resistance (MDR) phenomenon was assessed via cellular uptake of 99mTc-sestamibi (MIBI), a known substrate for P-glycoprotein. A 15-mer phosphorothioate antisense ODN complementary to the sequences located at −1 to 14 of mdr1 mRNA and its corresponding sense ODN were conjugated with the cyclic anhydride of diethylene triamine penta-acetic acid (cDTPA) via an amino group linked to the terminal phosphate at the 5′ end at pH 8–9. The DTPA–ODN complexes at concentrations of 0.1–17.4 μM were reacted with 111InCl3 at pH 5 for 1 h. The hybridization affinity of labeled ODN was evaluated with size-exclusion high-performance liquid chromatography following incubation with the complementary sequence. Cellular uptake of labeled ODN was examined in vitro. Furthermore, enhancing effects of synthetic lipid carriers (Transfast) on transmembrane delivery of ODN were assessed.
Results
P388/R cells displayed intense mdr1 mRNA expression in comparison with P388/S cells. 99mTc-MIBI uptake in P388/S cells was higher than that in P388/R cells. Specific radioactivity up to 1,634 MBq/nmol was achieved via elevation of added radioactivity relative to ODN molar amount. The hybridization affinity of antisense 111In-ODN was preserved at approximately 85% irrespective of specific activity. Cellular uptake of antisense 111In-ODN did not differ from that of sense 111In-ODN in either P388/S cells or P388/R cells. However, lipid carrier incorporation significantly increased transmembrane delivery of 111In-ODN; moreover, specific uptake of antisense 111In-ODN was demonstrated in P388/R cells.
Conclusion
Radiolabeling of ODN at high specific radioactivity and specific uptake of antisense 111In-ODN in drug-resistant cells may facilitate future gene imaging of mdr1 mRNA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Motomura S, Motoji T, Takanashi M, Wang YH, Shiozaki H, Sugawara I, et al. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood 1998;91:3163–71.
Ballinger JR. Imaging multidrug resistance with radiolabeled substrates for P-glycoprotein and multidrug resistance protein. Cancer Biother Radiopharm 2001;16:1–7.
Ak I, Aslan V, Vardareli E, Gulbas Z. Assessment of the P-glycoprotein expression by 99mTc-MIBI bone marrow imaging in patients with untreated leukemia. Nucl Med Commun 2003;24:397–402.
Sasaki M, Kuwabara Y, Ichiya Y, Yoshida T, Nakagawa M, Soeda H, et al. Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT. J Nucl Med 1999;40:1778–83.
Kinuya S, Li X-F, Yokoyama K, Mori H, Shiba K, Watanabe N, et al. Reduction of 99mTc-sestamibi and 99mTc-tetrofosmin uptake in MRP-expressing breast cancer cells under hypoxic conditions is independent of MRP function. Eur J Nucl Med Mol Imaging 2003;30:1529–31.
Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, Dewanjee S, Serafini AN, Lopez DM, Sfakianakis GN. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J Nucl Med 1994;35:1054–63.
Urbain JC, Shore SK, Vekemans MC, Cosenza SC, Deriel K, Patel GV, et al. Scintigraphic imaging of oncogenes with antisense probes: does it make sense? Eur J Nucl Med 1995;22:499–504.
Hnatowich DJ. Antisense imaging: where are we now? Cancer Biother Radiopharm 2000;15:447–57.
Nakashima E, Matsushita R, Negishi H, Nomura M, Harada S, Yamamoto H, et al. Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotides. J Pharm Sci 1995;84:1205–9.
Barrand MA, Twentyman PR. Differential recognition of mdr1a and mdr1b gene products in multidrug resistant mouse tumor cell lines by different monoclonal antibodies. Br J Cancer 1992;65:239–45.
Fujibayashi Y, Yoshimi E, Waki A, Sakahara H, Saga T, Konishi J, et al. A novel 111In-labeled antisense DNA probe with multi-chelating sites (MCS-probe) showing high specific radioactivity and labeling efficiency. Nucl Med Biol 1999;26:17–21.
Hnatowich DJ, Winnard PJ, Virzi F, Fogarasi M, Sano T, Smith CL. Labeling deoxyribonucleic acid ODNs with 99mTc. J Nucl Med 1995;36:2306–14.
Belikova AM, Zarytova VF, Grineva NI. Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloroethylamine and nitrogen mustard residues. Tetrahedron Lett 1967;37:3557–62.
Karamychev VN, Reed MW, Neumann RD, Panyutin IG. Distribution of DNA strand breaks produced by iodine-123 and indium-111 in synthetic oligodeoxynucleotides. Acta Oncol 2000;39:687–92.
Zhang YM, Liu N, Zhu ZH, Rusckowski M, Hnatowich DJ. Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA. Eur J Nucl Med 2000;27:1700–7.
Touboul M, Gauchez AS, Dhardemare ADM, Lunardi J, Deverre JR, Pernin C, et al. Early detection of chemoresistance in vivo through the use of a radiolabeled antisense oligonucleotide. Anticancer Res 2002;22:3349–56.
Velculescu VE. Tantalizing transcriptomes-SAGE and its use in global gene expression analysis. Science 1999;286:1491–2.
Gambhir SS, Barrio JR, Herschman HR, Phelps ME. Imaging gene expression: principles and assays. J Nucl Cardiol 1999;6:219–33.
Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, et al. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci U S A 1989;86:3473–8.
Sato N, Kobayashi H, Saga T, Nakamoto Y, Ishimori T, Togashi K, et al. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res 2001;7:3606–12.
Urbain JC. Sense, antisense, and common sense. J Nucl Med 2001;42:1670–1.
Thierry AR, Rahman A, Dritschilo A. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligonucleotides. Biochem Biophys Res Commun 1993;190:952–60.
Farhood H, Serbina N, Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta 1995;1235:289–95.
Akhtar S, Hughes MD, Khan A, Bibby M, Hussain M, Nawaz Q, et al. The delivery of antisense therapeutics. Adv Drug Deliv Rev 2000;44:3–21.
Semple SC, Klimuk SK, Harasym TO, Dos Santos N, Ansell SM, Wong KF, et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 2001;1510:152–66.
Acknowledgements
This study was supported by a Grant-in-Aid for Scientific Research (B-2: 13470180, 13877137) from the Ministry of Education, Science and Culture, Japan. We are grateful to Dr. Hui Li, Associate Professor Hideto Yonekura and Professor Hiroshi Yamamoto of the Second Department of Biochemistry, Kanazawa University, for their technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bai, J., Yokoyama, K., Kinuya, S. et al. In vitro detection of mdr1 mRNA in murine leukemia cells with 111In-labeled oligonucleotide. Eur J Nucl Med Mol Imaging 31, 1523–1529 (2004). https://doi.org/10.1007/s00259-004-1666-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-004-1666-y